Neurelis, Inc. is an innovation-driven neuroscience company focused on the development and commercialization of product candidates and innovative delivery technologies for the broader central nervous system (CNS), including epilepsy and psychiatry. In 2020, Neurelis reached a milestone in patient care with its first FDA-approved treatment. For information, please visit http://www.neurelis.com.

For information, please visit http://www.neurelis.com.